Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brachytherapy | 27 | 2024 | 1248 | 6.590 |
Why?
|
Prostatic Neoplasms | 33 | 2024 | 11124 | 2.720 |
Why?
|
Androgen Antagonists | 12 | 2024 | 1377 | 1.590 |
Why?
|
Prostate-Specific Antigen | 11 | 2024 | 2494 | 1.310 |
Why?
|
Radiotherapy Dosage | 14 | 2024 | 2879 | 0.950 |
Why?
|
Prostatectomy | 8 | 2020 | 1890 | 0.880 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2022 | 2020 | 0.870 |
Why?
|
Endometrial Neoplasms | 5 | 2022 | 1353 | 0.800 |
Why?
|
Radiation Pneumonitis | 2 | 2018 | 104 | 0.710 |
Why?
|
Radiation Injuries | 3 | 2023 | 1180 | 0.680 |
Why?
|
Radiographic Image Enhancement | 2 | 2018 | 885 | 0.630 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2021 | 806 | 0.600 |
Why?
|
Organs at Risk | 2 | 2016 | 346 | 0.560 |
Why?
|
Luminescence | 1 | 2016 | 137 | 0.550 |
Why?
|
Movement | 3 | 2007 | 1471 | 0.540 |
Why?
|
Ear Neoplasms | 1 | 2016 | 117 | 0.540 |
Why?
|
Beta Particles | 1 | 2015 | 50 | 0.530 |
Why?
|
Calcinosis | 3 | 2010 | 1499 | 0.530 |
Why?
|
Ear Canal | 1 | 2016 | 146 | 0.530 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2016 | 102 | 0.530 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2021 | 1524 | 0.510 |
Why?
|
Four-Dimensional Computed Tomography | 2 | 2017 | 145 | 0.510 |
Why?
|
Parotid Gland | 1 | 2015 | 168 | 0.490 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2023 | 1624 | 0.480 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 530 | 0.460 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4851 | 0.450 |
Why?
|
Luminescent Measurements | 1 | 2015 | 405 | 0.450 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 693 | 0.410 |
Why?
|
Tomography, X-Ray Computed | 6 | 2018 | 20129 | 0.400 |
Why?
|
Watchful Waiting | 5 | 2019 | 492 | 0.400 |
Why?
|
Radiotherapy | 2 | 2018 | 1533 | 0.400 |
Why?
|
Radiation Oncology | 3 | 2022 | 555 | 0.390 |
Why?
|
Heart | 3 | 2010 | 4467 | 0.390 |
Why?
|
Radionuclide Imaging | 1 | 2015 | 2031 | 0.390 |
Why?
|
Radiosurgery | 4 | 2021 | 1329 | 0.370 |
Why?
|
Neoplasms, Experimental | 1 | 2015 | 1276 | 0.360 |
Why?
|
Retrospective Studies | 23 | 2022 | 77449 | 0.350 |
Why?
|
Respiration | 1 | 2015 | 1653 | 0.320 |
Why?
|
Healthcare Disparities | 3 | 2022 | 3158 | 0.320 |
Why?
|
Surgery, Computer-Assisted | 1 | 2016 | 1018 | 0.320 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2016 | 2016 | 0.310 |
Why?
|
Magnetic Resonance Imaging | 6 | 2023 | 35421 | 0.300 |
Why?
|
Aged | 30 | 2023 | 163280 | 0.300 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2021 | 1770 | 0.300 |
Why?
|
Hodgkin Disease | 1 | 2015 | 1415 | 0.290 |
Why?
|
SEER Program | 4 | 2020 | 1508 | 0.290 |
Why?
|
Salvage Therapy | 4 | 2023 | 1275 | 0.280 |
Why?
|
Prostate | 4 | 2023 | 1774 | 0.270 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2016 | 3760 | 0.270 |
Why?
|
Male | 36 | 2024 | 350118 | 0.260 |
Why?
|
Artifacts | 4 | 2020 | 1904 | 0.260 |
Why?
|
Humans | 57 | 2024 | 744343 | 0.250 |
Why?
|
Combined Modality Therapy | 6 | 2020 | 8642 | 0.240 |
Why?
|
Survival Rate | 6 | 2020 | 12788 | 0.240 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 9239 | 0.240 |
Why?
|
Lung Neoplasms | 3 | 2018 | 13102 | 0.230 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13695 | 0.230 |
Why?
|
Proportional Hazards Models | 6 | 2022 | 12354 | 0.230 |
Why?
|
Databases, Factual | 7 | 2019 | 7729 | 0.220 |
Why?
|
Atherosclerosis | 2 | 2007 | 3445 | 0.200 |
Why?
|
Belgium | 1 | 2021 | 103 | 0.200 |
Why?
|
Risk Assessment | 5 | 2020 | 23338 | 0.190 |
Why?
|
Middle Aged | 25 | 2021 | 213383 | 0.190 |
Why?
|
Lung | 2 | 2017 | 9856 | 0.180 |
Why?
|
Tumor Burden | 2 | 2023 | 1915 | 0.180 |
Why?
|
Hyaluronic Acid | 1 | 2023 | 491 | 0.170 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 1184 | 0.170 |
Why?
|
Phantoms, Imaging | 4 | 2022 | 2480 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11524 | 0.160 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2018 | 8949 | 0.160 |
Why?
|
Urethra | 2 | 2021 | 408 | 0.160 |
Why?
|
ROC Curve | 1 | 2006 | 3527 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 221 | 0.160 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 705 | 0.150 |
Why?
|
Propensity Score | 3 | 2021 | 1781 | 0.150 |
Why?
|
Neoplasm Staging | 7 | 2021 | 11031 | 0.150 |
Why?
|
Genital Neoplasms, Female | 1 | 2023 | 523 | 0.150 |
Why?
|
Acceleration | 2 | 2007 | 181 | 0.150 |
Why?
|
Cervix Uteri | 1 | 2021 | 590 | 0.150 |
Why?
|
Carcinoma, Endometrioid | 1 | 2019 | 271 | 0.140 |
Why?
|
Disease-Free Survival | 3 | 2017 | 6895 | 0.140 |
Why?
|
Prognosis | 6 | 2020 | 29063 | 0.140 |
Why?
|
Algorithms | 4 | 2018 | 13881 | 0.140 |
Why?
|
Androgens | 1 | 2024 | 1281 | 0.140 |
Why?
|
Urethral Stricture | 1 | 2016 | 51 | 0.140 |
Why?
|
Feasibility Studies | 2 | 2023 | 5078 | 0.140 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2021 | 3479 | 0.140 |
Why?
|
Follow-Up Studies | 6 | 2020 | 39050 | 0.130 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2077 | 0.130 |
Why?
|
Vagina | 1 | 2020 | 825 | 0.120 |
Why?
|
Cohort Studies | 7 | 2021 | 40561 | 0.120 |
Why?
|
Morbidity | 1 | 2019 | 1769 | 0.120 |
Why?
|
Female | 18 | 2023 | 380194 | 0.110 |
Why?
|
Logistic Models | 5 | 2019 | 13408 | 0.110 |
Why?
|
Neoplasms, Second Primary | 1 | 2021 | 1061 | 0.110 |
Why?
|
Survival Analysis | 4 | 2019 | 10252 | 0.110 |
Why?
|
Regression Analysis | 2 | 2015 | 6459 | 0.110 |
Why?
|
Time Factors | 3 | 2021 | 40075 | 0.110 |
Why?
|
Adult | 13 | 2023 | 214055 | 0.110 |
Why?
|
Tidal Volume | 1 | 2015 | 490 | 0.110 |
Why?
|
Radiotherapy, Conformal | 1 | 2016 | 548 | 0.110 |
Why?
|
Treatment Outcome | 6 | 2020 | 63114 | 0.110 |
Why?
|
Travel | 1 | 2018 | 788 | 0.110 |
Why?
|
Consensus | 1 | 2021 | 2959 | 0.100 |
Why?
|
Prospective Studies | 5 | 2023 | 53288 | 0.100 |
Why?
|
Fellowships and Scholarships | 1 | 2020 | 1076 | 0.100 |
Why?
|
Kinetics | 2 | 2019 | 6473 | 0.100 |
Why?
|
Sample Size | 1 | 2015 | 845 | 0.100 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1584 | 0.100 |
Why?
|
Reproducibility of Results | 3 | 2018 | 19905 | 0.100 |
Why?
|
Rectum | 1 | 2016 | 904 | 0.100 |
Why?
|
Radiometry | 1 | 2016 | 800 | 0.100 |
Why?
|
Disease Management | 2 | 2019 | 2459 | 0.090 |
Why?
|
Patient Compliance | 1 | 2020 | 2684 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2214 | 0.090 |
Why?
|
Cochlea | 1 | 2016 | 828 | 0.090 |
Why?
|
Sensitivity and Specificity | 3 | 2021 | 14722 | 0.090 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2886 | 0.080 |
Why?
|
Catheters | 2 | 2023 | 425 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2021 | 1587 | 0.080 |
Why?
|
Mice, Nude | 1 | 2015 | 3689 | 0.080 |
Why?
|
Aged, 80 and over | 9 | 2020 | 57776 | 0.080 |
Why?
|
United States | 7 | 2022 | 69872 | 0.080 |
Why?
|
Boston | 1 | 2021 | 9313 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3086 | 0.070 |
Why?
|
Area Under Curve | 1 | 2010 | 1654 | 0.070 |
Why?
|
Filtration | 1 | 2006 | 234 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2942 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2020 | 5137 | 0.060 |
Why?
|
Observer Variation | 1 | 2010 | 2593 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9959 | 0.060 |
Why?
|
User-Computer Interface | 1 | 2010 | 1431 | 0.060 |
Why?
|
Registries | 1 | 2019 | 8089 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7913 | 0.060 |
Why?
|
Research Design | 1 | 2019 | 5987 | 0.060 |
Why?
|
Recurrence | 1 | 2015 | 8340 | 0.060 |
Why?
|
Piroxicam | 1 | 2002 | 18 | 0.050 |
Why?
|
Child, Preschool | 2 | 2015 | 41006 | 0.050 |
Why?
|
Odds Ratio | 3 | 2020 | 9849 | 0.050 |
Why?
|
Rhodamines | 1 | 2002 | 183 | 0.050 |
Why?
|
Risk Factors | 2 | 2019 | 72290 | 0.050 |
Why?
|
Polyglycolic Acid | 1 | 2002 | 407 | 0.050 |
Why?
|
Information Storage and Retrieval | 1 | 2006 | 824 | 0.050 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 3047 | 0.050 |
Why?
|
Colposcopy | 1 | 2021 | 144 | 0.050 |
Why?
|
Internship and Residency | 1 | 2020 | 5788 | 0.050 |
Why?
|
Delphi Technique | 1 | 2023 | 778 | 0.050 |
Why?
|
Radioisotopes | 1 | 2021 | 499 | 0.050 |
Why?
|
Quality of Life | 1 | 2021 | 12804 | 0.040 |
Why?
|
Carcinosarcoma | 1 | 2020 | 108 | 0.040 |
Why?
|
Needles | 1 | 2022 | 449 | 0.040 |
Why?
|
Mice | 2 | 2016 | 81183 | 0.040 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16689 | 0.040 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2020 | 221 | 0.040 |
Why?
|
Young Adult | 2 | 2015 | 56430 | 0.040 |
Why?
|
Selection Bias | 1 | 2020 | 371 | 0.040 |
Why?
|
Calcium | 1 | 2010 | 5756 | 0.040 |
Why?
|
Linear Models | 1 | 2007 | 5952 | 0.040 |
Why?
|
Lactic Acid | 1 | 2002 | 1133 | 0.040 |
Why?
|
Child | 2 | 2015 | 77709 | 0.040 |
Why?
|
Adolescent | 2 | 2015 | 85781 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6538 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2019 | 601 | 0.040 |
Why?
|
Heart Rate | 1 | 2007 | 4091 | 0.030 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2020 | 450 | 0.030 |
Why?
|
Education | 1 | 2019 | 543 | 0.030 |
Why?
|
Software | 1 | 2010 | 4443 | 0.030 |
Why?
|
Cryotherapy | 1 | 2017 | 155 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 288 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2020 | 681 | 0.030 |
Why?
|
Polymers | 1 | 2002 | 1621 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2971 | 0.030 |
Why?
|
Myocardium | 1 | 2007 | 4776 | 0.030 |
Why?
|
HeLa Cells | 1 | 2021 | 3128 | 0.030 |
Why?
|
Infant | 1 | 2016 | 35136 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2017 | 402 | 0.030 |
Why?
|
Triage | 1 | 2021 | 976 | 0.030 |
Why?
|
Animals | 2 | 2016 | 168757 | 0.030 |
Why?
|
Biocompatible Materials | 1 | 2002 | 1736 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 3870 | 0.030 |
Why?
|
Community Health Centers | 1 | 2017 | 430 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1928 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2006 | 4042 | 0.030 |
Why?
|
Neoplasms | 1 | 2021 | 21683 | 0.030 |
Why?
|
Forced Expiratory Volume | 1 | 2017 | 1743 | 0.030 |
Why?
|
Taxoids | 1 | 2015 | 666 | 0.030 |
Why?
|
Markov Chains | 1 | 2015 | 969 | 0.030 |
Why?
|
Models, Economic | 1 | 2015 | 713 | 0.020 |
Why?
|
Patient Selection | 1 | 2022 | 4215 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1372 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3743 | 0.020 |
Why?
|
Population Surveillance | 1 | 2019 | 2616 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 20822 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2021 | 3528 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8324 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3616 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2759 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2015 | 2416 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2015 | 1956 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3507 | 0.020 |
Why?
|
Clinical Competence | 1 | 2020 | 4687 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9687 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12245 | 0.010 |
Why?
|
Genomics | 1 | 2019 | 5720 | 0.010 |
Why?
|
Chemistry, Physical | 1 | 2002 | 156 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5391 | 0.010 |
Why?
|
Chemical Phenomena | 1 | 2002 | 518 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13284 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18370 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2002 | 964 | 0.010 |
Why?
|
Microspheres | 1 | 2002 | 777 | 0.010 |
Why?
|
Particle Size | 1 | 2002 | 1642 | 0.010 |
Why?
|